Igor A Astsaturov

List of Publications by Year
in descending order

58	4,768	136950	149698
papers	citations	32 h-index	56 g-index

61	61	61	8443
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	28.4	2,012
2	Aurora A kinase (AURKA) in normal and pathological cell division. Cellular and Molecular Life Sciences, 2013, 70, 661-687.	5.4	349
3	Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Science Signaling, 2010, 3, ra67.	3.6	131
4	Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 2832-2838.	1.5	128
5	Molecular Pathways: Sterols and Receptor Signaling in Cancer. Clinical Cancer Research, 2014, 20, 28-34.	7.0	104
6	Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblastâ€“Driven Nutritional Support and Immunosuppression. Cancer Discovery, 2021, 11, 446-479.	9.4	97
7	Cholesterol Pathway Inhibition Induces TGF-Î² Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell, 2020, 38, 567-583.e11.	16.8	91
8	Chemotherapy and signaling. Cancer Biology and Therapy, 2010, 10, 839-853.	3.4	88
9	Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. British Journal of Cancer, 2016, 115, 564-570.	6.4	88
10	Type I Diabetes and Multiple Sclerosis Patients Target Islet Plus Central Nervous System Autoantigens; Nonimmunized Nonobese Diabetic Mice Can Develop Autoimmune Encephalitis. Journal of Immunology, 2001, 166, 2831-2841.	0.8	84
11	Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 3601-3607.	1.5	78
12	Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets, 2009, 13, 339-362.	3.4	77
13	Regulation of cholesterol biosynthesis and cancer signaling. Current Opinion in Pharmacology, 2012, 12, 710-716.	3.5	74
14	Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling, 2009, 21, 1255-1268.	3.6	72
15	Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opinion on Investigational Drugs, 2017, 26, 531-540.	4.1	71
16	Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Reports, 2015, 12, 1927-1938.	6.4	67
17	Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 1587-1609.	3.4	63
18	Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation. Cancer Discovery, 2013, 3, 96-111.	9.4	58

#	Article	IF	Citations
19	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3â€“MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 6153-6163.	7.0	56
20	Aurora kinases in head and neck cancer. Lancet Oncology, The, 2013, 14, e425-e435.	10.7	55
21	Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer. Annals of Thoracic Surgery, 2015, 99, 270-276.	1.3	55
22	Primary SjÃ¶gren's syndrome and deficiency of ICA69. Lancet, The, 2002, 360, 1063-1069.	13.7	50
23	Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2016, 45, 1131-1135.	1.1	47
24	Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1375-1388.	7.0	46
25	Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer. Clinical Cancer Research, 2013, 19, 5053-5067.	7.0	45
26	Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer, 2006, 106, 890-899.	4.1	44
27	Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clinical Cancer Research, 2003, 9, 4347-55.	7.0	43
28	EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 2486-2497.	4.1	42
29	EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer. Current Cancer Drug Targets, 2006, 6, 691-710.	1.6	40
30	Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer, 2012, 106, 748-755.	6.4	38
31	Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Review of Anticancer Therapy, 2006, 6, 1179-1193.	2.4	35
32	Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology, Immunotherapy, 2012, 61, 49-61.	4.2	35
33	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget, 2017, 8, 81776-81793.	1.8	34
34	Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 70-75.	1.3	33
35	DUSP6 regulates drug sensitivity by modulating DNA damage response. British Journal of Cancer, 2013, 109, 1063-1071.	6.4	31
36	Overview of Monoclonal Antibodies and Small Molecules Targeting the Epidermal Growth Factor Receptor Pathway in Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, S71-S80.	2.3	27

#	Article	IF	Citations
37	Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports, 2021, 36, 109599.	6.4	27
38	ICA69null Nonobese Diabetic Mice Develop Diabetes, but Resist Disease Acceleration by Cyclophosphamide. Journal of Immunology, 2002, 168, 475-482.	0.8	26
39	LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. British Journal of Cancer, 2017, 116, 1203-1207.	6.4	25
40	EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer. Current Cancer Drug Targets, 2007, 7, 650-665.	1.6	24
41	TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis. Molecular Medicine, 2013, 19, 149-159.	4.4	24
42	HSP90 Inhibitorâ€“SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors. Molecular Cancer Therapeutics, 2015, 14, 2422-2432.	4.1	24
43	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	5.9	19
44	Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle, 2014, 13, 2172-2191.	2.6	14
45	Successful Imatinib Therapy for Neuroendocrine Carcinoma With ActivatingKITMutation: A Case Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 847-852.	4.9	14
46	Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer. JCO Clinical Cancer Informatics, 2021, 5, 125-133.	2.1	13
47	The Emerging Role of Cetuximab in Head and Neck Cancer: A 2007 Perspective. Cancer Investigation, 2008, 26, 96-103.	1.3	12
48	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget, 2017, 8, 4399-4409.	1.8	12
49	Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 393-398.	1.3	7
50	Platelet microRNAs inhibit primary tumor growth via broad modulation of tumor cell mRNA expression in ectopic pancreatic cancer in mice. PLoS ONE, 2021, 16, e0261633.	2.5	7
51	Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treatment and Research, 2008, 139, 135-52.	0.5	6
52	CRISPR/Cas9 Technique for Identification of Genes Regulating Oxaliplatin Resistance of Pancreatic Cancer Cell Line. BioNanoScience, 2017, 7, 97-100.	3.5	5
53	Future Clinical Trials. Surgical Oncology Clinics of North America, 2017, 26, 791-797.	1.5	4
54	Profiling of 1,350 neuroendocrine tumors for identification of multiple potential drug targets.. Journal of Clinical Oncology, 2014, 32, 4113-4113.	1.6	4

#	Article	IF	Citations
55	Abstract 721: Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer. , 2012, , .		2
56	Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer. Cancer Treatment and Research, 2008, , 132-149.	0.5	1
57	Preparation of mouse pancreatic tumor for single-cell RNA sequencing and analysis of the data. STAR Protocols, 2021, 2, 100989.	1.2	1
58	The right and wrong of DOKing the nuclear receptor. EBioMedicine, 2016, 8, 7.	6.1	0